MCID: VRR004
MIFTS: 55

Verrucous Carcinoma

Categories: Cancer diseases, Oral diseases

Aliases & Classifications for Verrucous Carcinoma

MalaCards integrated aliases for Verrucous Carcinoma:

Name: Verrucous Carcinoma 12 15
Verrucous Squamous Cell Carcinoma 12
Verrucous Squamous Carcinoma 12
Carcinoma, Verrucous 44
Carcinoma Verrucous 55
Warty Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3737
MeSH 44 D018289
NCIt 50 C3781
SNOMED-CT 68 89906000
UMLS 73 C0206706

Summaries for Verrucous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that is a diffuse, papillary, non metastasizing, well differentiated, malignant neoplasm of epidermis or oral epithelium.

MalaCards based summary : Verrucous Carcinoma, also known as verrucous squamous cell carcinoma, is related to squamous cell carcinoma and vulva squamous cell carcinoma. An important gene associated with Verrucous Carcinoma is MSN (Moesin), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Fluorouracil and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, skin and bone, and related phenotypes are Decreased viability with paclitaxel and cellular

Wikipedia : 76 Verrucous carcinoma (VC) is an uncommon variant of squamous cell carcinoma. This form of cancer is... more...

Related Diseases for Verrucous Carcinoma

Diseases related to Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 222)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 30.8 CCND1 CDKN2A RB1 TP53
2 vulva squamous cell carcinoma 30.3 CDKN2A TP53
3 oral leukoplakia 30.3 CDKN2A TP53
4 papilloma 30.2 CCND1 CDKN2A KRT10 RB1 TP53
5 inverted papilloma 30.1 CCND1 CDKN2A TP53
6 oral cancer 30.1 CCND1 CDKN2A TP53
7 scrotal carcinoma 30.0 CDKN2A TP53
8 squamous cell carcinoma, head and neck 30.0 CCND1 CDKN2A RB1 TP53
9 squamous cell papilloma 29.9 CDKN2A TP53
10 adenocarcinoma 29.9 CCND1 CDKN2A RB1 TP53
11 larynx verrucous carcinoma 12.3
12 supraglottis verrucous carcinoma 12.3
13 esophagus verrucous carcinoma 12.3
14 cervical verrucous carcinoma 12.3
15 vulva verrucous carcinoma 12.3
16 glottis verrucous carcinoma 12.2
17 subglottis verrucous carcinoma 12.2
18 urethral verrucous carcinoma 12.1
19 penis non-invasive verrucous carcinoma 12.1
20 penis verrucous carcinoma 12.1
21 buschke lowenstein tumor 11.5
22 anal buschke-lowenstein tumor 11.4
23 proliferative verrucous leukoplakia 11.2
24 bladder verrucous squamous cell carcinoma 11.1
25 penile cancer, adult 10.4
26 oral squamous cell carcinoma 10.4
27 vulvar adenocarcinoma 10.3 RB1 TP53
28 lichen planus 10.3
29 bladder squamous cell carcinoma 10.2 CDKN2A TP53
30 ring chromosome 7 10.2 MDM2 TP53
31 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
32 zika virus infection 10.2 MDM2 TP53
33 spitz nevus 10.2 CDKN2A TP53
34 bladder carcinoma in situ 10.2 CDKN2A TP53
35 gallbladder adenoma 10.2 CDKN2A RB1
36 actinic cheilitis 10.2 MDM2 TP53
37 cheilitis 10.2 MDM2 TP53
38 vulvar disease 10.2 CDKN2A TP53
39 nasal cavity adenocarcinoma 10.2 CDKN2A TP53
40 bartholin's gland disease 10.2 CDKN2A TP53
41 sclerosing liposarcoma 10.2 MDM2 TP53
42 anal squamous cell carcinoma 10.2 CDKN2A TP53
43 megaesophagus 10.2 CDKN2A TP53
44 lip cancer 10.2 MDM2 TP53
45 glycogen-rich clear cell breast carcinoma 10.2 CDKN2A TP53
46 gastric adenosquamous carcinoma 10.2 CDKN2A TP53
47 anogenital venereal wart 10.2 CDKN2A TP53
48 spindle cell lipoma 10.2 MDM2 RB1
49 cervix uteri carcinoma in situ 10.2 CDKN2A TP53
50 uterus carcinoma in situ 10.2 CDKN2A TP53

Graphical network of the top 20 diseases related to Verrucous Carcinoma:



Diseases related to Verrucous Carcinoma

Symptoms & Phenotypes for Verrucous Carcinoma

GenomeRNAi Phenotypes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00293-A 8.8 KRT10 SLC2A1 TP53

MGI Mouse Phenotypes related to Verrucous Carcinoma:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 CCND1 CDKN2A LRIG1 MDM2 RB1 SLC2A1
2 behavior/neurological MP:0005386 10.08 CCND1 CDKN2A LRIG1 MDM2 RB1 SLC2A1
3 homeostasis/metabolism MP:0005376 10.06 CCND1 CDKN2A LRIG1 MDM2 RB1 SLC2A1
4 immune system MP:0005387 9.98 CCND1 CDKN2A LRIG1 MDM2 RB1 TP53
5 digestive/alimentary MP:0005381 9.97 CCND1 CDKN2A LRIG1 MDM2 RB1 TP53
6 endocrine/exocrine gland MP:0005379 9.95 CCND1 CDKN2A LRIG1 MDM2 RB1 TP53
7 nervous system MP:0003631 9.92 CCND1 CDKN2A LRIG1 MDM2 RB1 SLC2A1
8 craniofacial MP:0005382 9.91 CCND1 LRIG1 MDM2 RB1 TP53
9 integument MP:0010771 9.88 CCND1 CDKN2A LRIG1 MDM2 RB1 TP53
10 neoplasm MP:0002006 9.85 CCND1 CDKN2A LRIG1 MDM2 RB1 TP53
11 no phenotypic analysis MP:0003012 9.73 CDKN2A LRIG1 MDM2 RB1 SLC2A1 TP53
12 normal MP:0002873 9.63 CCND1 LRIG1 MDM2 MSN RB1 TP53
13 pigmentation MP:0001186 9.26 CDKN2A MDM2 RB1 TP53
14 skeleton MP:0005390 9.17 CCND1 CDKN2A LRIG1 MDM2 RB1 TP53

Drugs & Therapeutics for Verrucous Carcinoma

Drugs for Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
2
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
3
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
5
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
6
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
7
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
10
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
11
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
12
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 6006 143
13
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
14
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
15
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
16
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
17
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
18
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
19
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
23 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
25 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
26 Antimetabolites Phase 3,Phase 2,Phase 1
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
29 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
31 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
32 Antimitotic Agents Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Anti-Infective Agents Phase 2, Phase 3,Phase 1
35 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
36 Autonomic Agents Phase 3,Phase 2,Not Applicable
37 Histamine Antagonists Phase 3
38 Psychotropic Drugs Phase 3
39 Antidepressive Agents Phase 3
40
Histamine Phosphate Phase 3 51-74-1 65513
41 Antidepressive Agents, Tricyclic Phase 3
42 Central Nervous System Depressants Phase 3
43 Adjuvants, Anesthesia Phase 3
44 Anesthetics, Intravenous Phase 3
45 Analgesics, Opioid Phase 3
46 Anesthetics, General Phase 3
47 Analgesics Phase 3
48 Narcotics Phase 3
49 Anesthetics Phase 3
50 Vitamin B9 Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
2 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
5 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
6 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
7 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
8 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
9 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
10 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
11 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
12 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
13 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
14 CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Withdrawn NCT01545687 Phase 3
15 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
16 Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
17 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
18 Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Unknown status NCT00721513 Phase 2 cisplatin;docetaxel;fluorouracil
19 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
20 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
21 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
22 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
23 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
24 Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer Completed NCT02048020 Phase 2 paclitaxel;carboplatin
25 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
26 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
27 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
28 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
29 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
30 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
31 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
32 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
33 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
34 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
35 Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
36 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
37 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
38 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
39 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
40 Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery Completed NCT00738868 Phase 2
41 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
42 Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
43 Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00720304 Phase 2 docetaxel;erlotinib hydrochloride
44 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
45 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
46 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
47 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
48 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
49 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
50 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Completed NCT00833261 Phase 2 cetuximab;cisplatin

Search NIH Clinical Center for Verrucous Carcinoma

Cochrane evidence based reviews: carcinoma, verrucous

Genetic Tests for Verrucous Carcinoma

Anatomical Context for Verrucous Carcinoma

MalaCards organs/tissues related to Verrucous Carcinoma:

41
Cervix, Skin, Bone, Liver, Lung, T Cells, Tongue

Publications for Verrucous Carcinoma

Articles related to Verrucous Carcinoma:

(show top 50) (show all 654)
# Title Authors Year
1
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications. ( 30111295 )
2018
2
BCL-X expression in oral cancer: Comparison between oral squamous cell carcinoma and verrucous carcinoma. ( 29652014 )
2018
3
Verrucous carcinoma of the esophagus: A rare entity with a difficult diagnosis. ( 29452967 )
2018
4
Two Cases of Verrucous Carcinoma: Revisiting the Definition. ( 29540646 )
2018
5
A Case of Oral Florid Papillomatosis (Verrucous Carcinoma) With Lack of Evidence for Human Papillomavirus Involvement. ( 29697424 )
2018
6
Verrucous carcinoma of the esophagus-remains a diagnostic enigma. ( 29748561 )
2018
7
Mistaken Diabetic Ulcers: A Case of Bilateral Foot Verrucous Carcinoma. ( 29796321 )
2018
8
Corrigendum to "Mistaken Diabetic Ulcers: A Case of Bilateral Foot Verrucous Carcinoma". ( 29849220 )
2018
9
Recalcitrant lip verrucous carcinoma successfully treated with acitretin after carbon dioxide laser ablation. ( 29998178 )
2018
10
Verrucous Carcinoma Arising in Association With Giant Condyloma. ( 30185090 )
2018
11
Treatment of verrucous carcinoma in penis with topical aminolevulinic acid photodynamic therapy: An effective and safe treatment method. ( 30205190 )
2018
12
Verrucous carcinoma arising from a previous cystic lesion: a case report. ( 30397593 )
2018
13
Human papillomavirus infection is not involved in esophageal verrucous carcinoma. ( 30423307 )
2018
14
Anogenital Verrucous Carcinoma-A case report. ( 30508696 )
2018
15
A clitoral verrucous carcinoma in an area of lichen planus has aggressive features. ( 28061900 )
2017
16
Comorbidity between HTLV-1-associated adult T-cell lymphoma/leukemia and verrucous carcinoma: a case report. ( 28559645 )
2017
17
A population-based analysis of verrucous carcinoma of the oral cavity. ( 28850720 )
2017
18
Adjuvant radiotherapy is not supported in patients with verrucous carcinoma of the oral cavity. ( 28150306 )
2017
19
Research on miRNA-195 and target gene CDK6 in oral verrucous carcinoma. ( 28621315 )
2017
20
Local Excision for the Treatment of Penile Verrucous Carcinoma. ( 28417078 )
2017
21
Diagnostic Biomarkers in Oral Verrucous Carcinoma: A Systematic Review. ( 27924463 )
2017
22
Human Papilloma Virus-Associated Lips Verrucous Carcinoma in HIV-Infected Male. ( 28565927 )
2017
23
Verrucous carcinoma of foot at an unusual site: Lessons to be learnt. ( 28702408 )
2017
24
Epidemiology and survival outcomes of sinonasal verrucous carcinoma in the United States. ( 28865078 )
2017
25
Rare "Inverted" Verrucous Carcinoma (Carcinoma Cuniculatum) of the Sacrogluteal Region: Case Report and Literature Review. ( 28381141 )
2017
26
Verrucous carcinoma of the oesophagus. ( 28116819 )
2017
27
Good Prognosis Went Badly: Fulminant Evolution of a 29-Year-Old Patient with Verrucous Carcinoma of the Cervix. ( 28498727 )
2017
28
Syringocystadenoma Papilliferum in Coexistence With Verrucous Carcinoma on the Face. ( 29112527 )
2017
29
Verrucous carcinoma of the buccal mucosa with extension to the cheek. ( 28319631 )
2017
30
Downregulation of Notch4 - a prognostic marker in distinguishing oral verrucous carcinoma from oral squamous cell carcinoma. ( 29162408 )
2017
31
A Giant Cutaneous Horn Projecting from Verrucous Carcinoma of Buccal Mucosa: A Rare Case Report. ( 28511519 )
2017
32
Verrucous carcinoma of the vulva: diagnosis and treatment. ( 28538888 )
2017
33
Malignant Transformation of a Site of Prior Diabetic Foot Ulceration to Verrucous Carcinoma: A Case Report. ( 29324428 )
2017
34
Oral Verrucous Carcinoma: Ten Year Experience from a Tertiary Care Hospital in India. ( 29333011 )
2017
35
Antioxidant enzymes in oral verrucous carcinoma. ( 27245640 )
2016
36
Investigation of the association between miRa89181b, Bcla892 and LRIG1 in oral verrucous carcinoma. ( 27509922 )
2016
37
The Akt/mTOR pathway is activated in verrucous carcinoma of the oral cavity. ( 26775690 )
2016
38
Reconstruction of the Auricular Defect After Excision of Verrucous Carcinoma. ( 26674896 )
2016
39
Pyoderma Vegetans Misdiagnosed as Verrucous Carcinoma. ( 26825160 )
2016
40
Subungual Verrucous Carcinoma of the Right Little Finger with Underlying Bony Invasion. ( 27746655 )
2016
41
Intraosseous verrucous carcinoma arising from an orthokeratinized odontogenic keratocyst: A report of a rarest entity. ( 27630514 )
2016
42
Oral verrucous hyperplasia versus oral verrucous carcinoma: A clinicopathologic dilemma revisited using p53 as immunohistochemical marker. ( 27721598 )
2016
43
Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a review of the literature. ( 27307433 )
2016
44
Verrucous carcinoma arising in a port wine stain. ( 26809361 )
2016
45
Verrucous Carcinoma of the Esophagus. ( 27803424 )
2016
46
An Unusual Presentation of Verrucous Carcinoma of the Foot with Bone Invasion. ( 28033059 )
2016
47
Endoscopic submucosal dissection for an atypical small verrucous carcinoma: a case report. ( 27036299 )
2016
48
Bilateral Plantar Verrucous Carcinoma. ( 28035248 )
2016
49
A Case of Squamous Cell Carcinoma in the External Auditory Canal Previously Treated for Verrucous Carcinoma. ( 27942606 )
2016
50
Verrucous carcinoma-an enigma: Case report and review. ( 27630507 )
2016

Variations for Verrucous Carcinoma

Expression for Verrucous Carcinoma

Search GEO for disease gene expression data for Verrucous Carcinoma.

Pathways for Verrucous Carcinoma

Pathways related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 CCND1 CDKN2A MDM2 MSN RB1 TP53
2
Show member pathways
13.56 CCND1 CDKN2A MDM2 RB1 TP53 TYMP
3
Show member pathways
12.96 CCND1 CDKN2A MDM2 RB1 TP53
4
Show member pathways
12.86 CCND1 MDM2 RB1 TP53
5
Show member pathways
12.79 CCND1 CDKN2A MDM2 RB1 TP53
6
Show member pathways
12.69 CCND1 CDKN2A MDM2 RB1 TP53
7
Show member pathways
12.66 CCND1 CDKN2A RB1 TP53
8 12.65 CCND1 CDKN2A MDM2 RB1 SLC2A1 TP53
9
Show member pathways
12.6 CCND1 MDM2 RB1 TP53
10
Show member pathways
12.48 CCND1 CDKN2A MDM2 RB1 TP53
11
Show member pathways
12.46 CCND1 MDM2 RB1 TP53
12 12.45 CCND1 CDKN2A MDM2 TP53
13
Show member pathways
12.41 CCND1 MDM2 SLC2A1 TP53
14 12.39 CCND1 CDKN2A MDM2 RB1 TP53
15
Show member pathways
12.3 CCND1 CDKN2A RB1 TP53
16 12.3 CCND1 CDKN2A RB1 SLC2A1 TP53
17
Show member pathways
12.28 CCND1 MDM2 TP53
18 12.24 CCND1 MDM2 RB1 TP53
19 12.24 CCND1 MDM2 MSN TP53
20
Show member pathways
12.24 CCND1 CDKN2A MDM2 RB1 TP53
21
Show member pathways
12.19 CCND1 MDM2 RB1 TP53
22 12.19 CCND1 CDKN2A MDM2 RB1 TP53
23
Show member pathways
12.14 CCND1 MDM2 RB1 TP53
24
Show member pathways
12.12 CCND1 CDKN2A RB1
25 12.11 CCND1 CDKN2A MDM2 RB1 TP53
26 12.08 CCND1 MDM2 RB1 TP53
27 12.03 CCND1 MDM2 TP53
28 11.99 CDKN2A MDM2 RB1 TP53
29 11.98 MDM2 RB1 TP53
30 11.94 CCND1 RB1 TP53
31 11.94 CCND1 MDM2 SLC2A1 TP53
32 11.92 CCND1 CDKN2A MDM2 TP53
33 11.86 CDKN2A MDM2 RB1 TP53
34 11.86 CCND1 CDKN2A MDM2 RB1 TP53
35 11.83 CCND1 RB1 TP53
36 11.81 CCND1 MDM2 RB1
37 11.76 CCND1 MDM2 RB1 TP53
38 11.7 CDKN2A MDM2 TP53
39
Show member pathways
11.7 CDKN2A MDM2 TP53
40 11.63 CDKN2A MDM2 RB1 TP53
41 11.6 CCND1 CDKN2A MDM2 RB1 TP53
42 11.56 CCND1 MDM2 TP53
43 11.47 MDM2 RB1 TP53
44 11.44 CCND1 MDM2 TP53
45 11.4 CDKN2A MDM2 SLC2A1 TP53
46 11.33 CCND1 CDKN2A RB1 TP53
47 11.28 CCND1 RB1
48 11.28 SLC2A1 TP53
49 11.27 CDKN2A MDM2 TP53
50 11.21 CCND1 TP53

GO Terms for Verrucous Carcinoma

Cellular components related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.23 CCND1 CDKN2A KRT10 MDM2 MSN SLC2A1

Biological processes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.88 CCND1 CDKN2A RB1 TP53
2 negative regulation of transcription, DNA-templated GO:0045892 9.84 CDKN2A MDM2 RB1 TP53
3 positive regulation of gene expression GO:0010628 9.76 CDKN2A MDM2 MSN TP53
4 cell cycle arrest GO:0007050 9.65 CDKN2A RB1 TP53
5 protein-containing complex assembly GO:0065003 9.61 MDM2 SLC2A1 TP53
6 protein sumoylation GO:0016925 9.58 CDKN2A MDM2
7 response to antibiotic GO:0046677 9.57 MDM2 TP53
8 response to steroid hormone GO:0048545 9.56 CCND1 MDM2
9 cellular response to gamma radiation GO:0071480 9.55 MDM2 TP53
10 negative regulation of cell cycle arrest GO:0071157 9.52 CCND1 MDM2
11 positive regulation of protein export from nucleus GO:0046827 9.51 MDM2 TP53
12 G1/S transition of mitotic cell cycle GO:0000082 9.5 CCND1 CDKN2A RB1
13 response to iron ion GO:0010039 9.49 CCND1 MDM2
14 replicative senescence GO:0090399 9.4 CDKN2A TP53
15 response to magnesium ion GO:0032026 9.37 CCND1 MDM2
16 amyloid fibril formation GO:1990000 9.26 CDKN2A MDM2
17 mitotic G1 DNA damage checkpoint GO:0031571 9.16 CCND1 TP53
18 Ras protein signal transduction GO:0007265 9.13 CDKN2A RB1 TP53
19 cellular response to actinomycin D GO:0072717 8.62 MDM2 TP53

Molecular functions related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.56 CCND1 CDKN2A MSN TP53
2 transcription factor binding GO:0008134 9.46 CCND1 CDKN2A RB1 TP53
3 enzyme binding GO:0019899 9.35 CCND1 MDM2 MSN RB1 TP53
4 SUMO transferase activity GO:0019789 9.32 CDKN2A MDM2
5 disordered domain specific binding GO:0097718 8.92 CDKN2A MDM2 RB1 TP53

Sources for Verrucous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....